InvestorsHub Logo
Followers 3
Posts 31
Boards Moderated 0
Alias Born 01/20/2018

Re: brooklyn13 post# 257

Saturday, 01/20/2018 5:02:59 PM

Saturday, January 20, 2018 5:02:59 PM

Post# of 428
I agree that it is highly possible Portage will invest in a conjunctive medication for chronic kidney disease patients. Cannabis derived medications for puritis and loss of appitite and other effects of chronic kidney disease could be considered. This would go well with Sentians present studies and Portage would have less restriction being out of Ontario Canada than some other US companies.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent PRTG News